Literature DB >> 30014611

Long-range genomic regulators of THBS1 and LTBP4 modify disease severity in duchenne muscular dystrophy.

Robert B Weiss1, Veronica J Vieland2,3,4, Diane M Dunn1, Yuuki Kaminoh5, Kevin M Flanigan5,3,6.   

Abstract

OBJECTIVE: Duchenne muscular dystrophy (DMD) is a severe X-linked recessive disease caused by loss-of-function dystrophin (DMD) mutations in boys, who typically suffer loss of ambulation by age 12. Previously, we reported that coding variants in latent transforming growth factor beta (TGFβ)-binding protein 4 (LTBP4) were associated with reduced TGFβ signaling and prolonged ambulation (p = 1.0 × 10-3 ) in DMD patients; this result was subsequently replicated by other groups. In this study, we evaluated whether additional DMD modifier genes are observed using whole-genome association in the original cohort.
METHODS: We performed a genome-wide association study (GWAS) for single-nucleotide polymorphisms (SNPs) influencing loss of ambulation (LOA) in the same cohort of 253 DMD patients used to detect the candidate association with LTBP4 coding variants. Gene expression and chromatin interaction databases were used to fine-map association signals above the threshold for genome-wide significance.
RESULTS: Despite the small sample size, two loci associated with prolonged ambulation met genome-wide significance and were tagged by rs2725797 (chr15, p = 6.6 × 10-9 ) and rs710160 (chr19, p = 4.7 × 10-8 ). Gene expression and chromatin interaction data indicated that the latter SNP tags regulatory variants of LTBP4, whereas the former SNP tags regulatory variants of thrombospondin-1 (THBS1): an activator of TGFβ signaling by direct binding to LTBP4 and an inhibitor of proangiogenic nitric oxide signaling.
INTERPRETATION: Together with previous evidence implicating LTBP4, the THBS1 modifier locus emphasizes the role that common regulatory variants in gene interaction networks can play in mitigating disease progression in muscular dystrophy. Ann Neurol 2018;84:234-245.
© 2018 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30014611      PMCID: PMC6168392          DOI: 10.1002/ana.25283

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  48 in total

1.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.

Authors:  Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson
Journal:  Am J Hum Genet       Date:  2003-12-15       Impact factor: 11.025

2.  Mendel: the Swiss army knife of genetic analysis programs.

Authors:  Kenneth Lange; Jeanette C Papp; Janet S Sinsheimer; Ram Sripracha; Hua Zhou; Eric M Sobel
Journal:  Bioinformatics       Date:  2013-04-22       Impact factor: 6.937

3.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

4.  SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy.

Authors:  E Pegoraro; E P Hoffman; L Piva; B F Gavassini; S Cagnin; M Ermani; L Bello; G Soraru; B Pacchioni; M D Bonifati; G Lanfranchi; C Angelini; A Kesari; I Lee; H Gordish-Dressman; J M Devaney; C M McDonald
Journal:  Neurology       Date:  2010-12-22       Impact factor: 9.910

5.  Evidence-based path to newborn screening for Duchenne muscular dystrophy.

Authors:  Jerry R Mendell; Chris Shilling; Nancy D Leslie; Kevin M Flanigan; Roula al-Dahhak; Julie Gastier-Foster; Kelley Kneile; Diane M Dunn; Brett Duval; Alexander Aoyagi; Cindy Hamil; Maha Mahmoud; Kandice Roush; Lauren Bird; Chelsea Rankin; Heather Lilly; Natalie Street; Ram Chandrasekar; Robert B Weiss
Journal:  Ann Neurol       Date:  2012-03       Impact factor: 10.422

6.  Flt-1 haploinsufficiency ameliorates muscular dystrophy phenotype by developmentally increased vasculature in mdx mice.

Authors:  Mayank Verma; Yoko Asakura; Hiroyuki Hirai; Shuichi Watanabe; Christopher Tastad; Guo-Hua Fong; Masatsugu Ema; Jarrod A Call; Dawn A Lowe; Atsushi Asakura
Journal:  Hum Mol Genet       Date:  2010-08-12       Impact factor: 6.150

7.  Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene.

Authors:  Kevin M Flanigan; Diane M Dunn; Andrew von Niederhausern; Payam Soltanzadeh; Michael T Howard; Jacinda B Sampson; Kathryn J Swoboda; Mark B Bromberg; Jerry R Mendell; Laura E Taylor; Christine B Anderson; Alan Pestronk; Julaine M Florence; Anne M Connolly; Katherine D Mathews; Brenda Wong; Richard S Finkel; Carsten G Bonnemann; John W Day; Craig McDonald; Robert B Weiss
Journal:  Hum Mutat       Date:  2011-03       Impact factor: 4.878

8.  Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions.

Authors:  Yong Zhou; Maria H Poczatek; Kathleen H Berecek; Joanne E Murphy-Ullrich
Journal:  Biochem Biophys Res Commun       Date:  2005-11-18       Impact factor: 3.575

9.  Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1.

Authors:  Takayuki Naito; Takao Masaki; David J Nikolic-Paterson; Chie Tanji; Noriaki Yorioka; Nobuoki Kohno
Journal:  Am J Physiol Renal Physiol       Date:  2003-10-28

10.  A reference panel of 64,976 haplotypes for genotype imputation.

Authors:  Shane McCarthy; Sayantan Das; Warren Kretzschmar; Olivier Delaneau; Andrew R Wood; Alexander Teumer; Hyun Min Kang; Christian Fuchsberger; Petr Danecek; Kevin Sharp; Yang Luo; Carlo Sidore; Alan Kwong; Nicholas Timpson; Seppo Koskinen; Scott Vrieze; Laura J Scott; He Zhang; Anubha Mahajan; Jan Veldink; Ulrike Peters; Carlos Pato; Cornelia M van Duijn; Christopher E Gillies; Ilaria Gandin; Massimo Mezzavilla; Arthur Gilly; Massimiliano Cocca; Michela Traglia; Andrea Angius; Jeffrey C Barrett; Dorrett Boomsma; Kari Branham; Gerome Breen; Chad M Brummett; Fabio Busonero; Harry Campbell; Andrew Chan; Sai Chen; Emily Chew; Francis S Collins; Laura J Corbin; George Davey Smith; George Dedoussis; Marcus Dorr; Aliki-Eleni Farmaki; Luigi Ferrucci; Lukas Forer; Ross M Fraser; Stacey Gabriel; Shawn Levy; Leif Groop; Tabitha Harrison; Andrew Hattersley; Oddgeir L Holmen; Kristian Hveem; Matthias Kretzler; James C Lee; Matt McGue; Thomas Meitinger; David Melzer; Josine L Min; Karen L Mohlke; John B Vincent; Matthias Nauck; Deborah Nickerson; Aarno Palotie; Michele Pato; Nicola Pirastu; Melvin McInnis; J Brent Richards; Cinzia Sala; Veikko Salomaa; David Schlessinger; Sebastian Schoenherr; P Eline Slagboom; Kerrin Small; Timothy Spector; Dwight Stambolian; Marcus Tuke; Jaakko Tuomilehto; Leonard H Van den Berg; Wouter Van Rheenen; Uwe Volker; Cisca Wijmenga; Daniela Toniolo; Eleftheria Zeggini; Paolo Gasparini; Matthew G Sampson; James F Wilson; Timothy Frayling; Paul I W de Bakker; Morris A Swertz; Steven McCarroll; Charles Kooperberg; Annelot Dekker; David Altshuler; Cristen Willer; William Iacono; Samuli Ripatti; Nicole Soranzo; Klaudia Walter; Anand Swaroop; Francesco Cucca; Carl A Anderson; Richard M Myers; Michael Boehnke; Mark I McCarthy; Richard Durbin
Journal:  Nat Genet       Date:  2016-08-22       Impact factor: 38.330

View more
  16 in total

Review 1.  What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?

Authors:  Dominic J Wells
Journal:  J Muscle Res Cell Motil       Date:  2019-07-09       Impact factor: 2.698

2.  Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications.

Authors:  Alberto A Zambon; Megan A Waldrop; Roxane Alles; Robert B Weiss; Sara Conroy; Melissa Moore-Clingenpeel; Stefano Previtali; Kevin M Flanigan
Journal:  Neurology       Date:  2021-12-22       Impact factor: 9.910

3.  High throughput screening for expanded CTG repeats in myotonic dystrophy type 1 using melt curve analysis.

Authors:  Russell J Butterfield; Carina Imburgia; Katie Mayne; Tara Newcomb; Diane M Dunn; Brett Duval; Marcia L Feldkamp; Nicholas E Johnson; Robert B Weiss
Journal:  Mol Genet Genomic Med       Date:  2021-02-24       Impact factor: 2.183

4.  Association of genetic mutations and loss of ambulation in childhood-onset dystrophinopathy.

Authors:  Gregory Haber; Kristin M Conway; Pangaja Paramsothy; Anindya Roy; Hobart Rogers; Xiang Ling; Nicholas Kozauer; Natalie Street; Paul A Romitti; Deborah J Fox; Han C Phan; Dennis Matthews; Emma Ciafaloni; Joyce Oleszek; Katherine A James; Maureen Galindo; Nedra Whitehead; Nicholas Johnson; Russell J Butterfield; Shree Pandya; Swamy Venkatesh; Venkatesh Atul Bhattaram
Journal:  Muscle Nerve       Date:  2020-11-17       Impact factor: 3.852

5.  Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy.

Authors:  Chiara Passarelli; Rita Selvatici; Alberto Carrieri; Francesca Romana Di Raimo; Maria Sofia Falzarano; Fernanda Fortunato; Rachele Rossi; Volker Straub; Katie Bushby; Mojgan Reza; Irina Zharaieva; Adele D'Amico; Enrico Bertini; Luciano Merlini; Patrizia Sabatelli; Paola Borgiani; Giuseppe Novelli; Sonia Messina; Marika Pane; Eugenio Mercuri; Mireille Claustres; Sylvie Tuffery-Giraud; Annemieke Aartsma-Rus; Pietro Spitali; Peter A C T'Hoen; Hanns Lochmüller; Kristin Strandberg; Cristina Al-Khalili; Ekaterina Kotelnikova; Michael Lebowitz; Elena Schwartz; Francesco Muntoni; Chiara Scapoli; Alessandra Ferlini
Journal:  Front Genet       Date:  2020-07-03       Impact factor: 4.599

6.  Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy.

Authors:  Maaike van Putten; Kayleigh Putker; Maurice Overzier; W A Adamzek; Svetlana Pasteuning-Vuhman; Jaap J Plomp; Annemieke Aartsma-Rus
Journal:  FASEB J       Date:  2019-04-01       Impact factor: 5.191

7.  Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.

Authors:  Francesco Muntoni; Joana Domingos; Adnan Y Manzur; Anna Mayhew; Michela Guglieri; Gautam Sajeev; James Signorovitch; Susan J Ward
Journal:  PLoS One       Date:  2019-09-03       Impact factor: 3.240

8.  Genetic modifiers of respiratory function in Duchenne muscular dystrophy.

Authors:  Luca Bello; Grazia D'Angelo; Matteo Villa; Aurora Fusto; Sara Vianello; Beatrice Merlo; Daniele Sabbatini; Andrea Barp; Sandra Gandossini; Francesca Magri; Giacomo P Comi; Marina Pedemonte; Paola Tacchetti; Valentina Lanzillotta; Federica Trucco; Adele D'Amico; Enrico Bertini; Guja Astrea; Luisa Politano; Riccardo Masson; Giovanni Baranello; Emilio Albamonte; Elisa De Mattia; Fabrizio Rao; Valeria A Sansone; Stefano Previtali; Sonia Messina; Gian Luca Vita; Angela Berardinelli; Tiziana Mongini; Antonella Pini; Marika Pane; Eugenio Mercuri; Andrea Vianello; Claudio Bruno; Eric P Hoffman; Lauren Morgenroth; Heather Gordish-Dressman; Craig M McDonald; Elena Pegoraro
Journal:  Ann Clin Transl Neurol       Date:  2020-04-28       Impact factor: 4.511

9.  Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects.

Authors:  Pasqualina Colella; Pauline Sellier; Manuel J Gomez; Maria G Biferi; Guillaume Tanniou; Nicolas Guerchet; Mathilde Cohen-Tannoudji; Maryse Moya-Nilges; Laetitia van Wittenberghe; Natalie Daniele; Bernard Gjata; Jacomina Krijnse-Locker; Fanny Collaud; Marcelo Simon-Sola; Severine Charles; Umut Cagin; Federico Mingozzi
Journal:  EBioMedicine       Date:  2020-10-09       Impact factor: 8.143

10.  Longitudinal motor function in proximal versus distal DMD pathogenic variants.

Authors:  Mathula Thangarajh; Luca Bello; Heather Gordish-Dressman
Journal:  Muscle Nerve       Date:  2021-07-23       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.